ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has entered into a definitive licensing agreement with US-based Instil Bio Inc. (Nasdaq: TIL), granting InstilBio development and commercial rights outside China for ImmuneOnco’s proprietary PD-L1- and VEGF-targeted bispecific antibody, IMM2510, and its next-generation anti-CTLA-4 antibody, IMM27M.
As per the agreement, a subsidiary of Instil will obtain global development and commercialization rights for both IMM2510 and IMM27M, excluding Greater China, which includes Taiwan, Macau, and Hong Kong, where ImmuneOnco will maintain its rights. ImmuneOnco is set to receive an upfront payment and potential near-term payments totaling up to USD 50 million, with the potential for additional development, regulatory, and commercial milestones exceeding USD 2 billion. The agreement also includes single-digit to low-double-digit percentage royalties on global ex-China sales.
IMM2510 is a novel bispecific antibody that combines an anti-PD-L1 antibody with a VEGF receptor trap, designed to bind multiple VEGF receptor ligands. It is distinguished by its smaller molecular weight, which may enhance tumor penetration, and its enhanced antibody-dependent cellular cytotoxicity (ADCC), aimed at improving tumor cell killing. IMM2510 has completed a dose-escalation clinical trial for advanced solid tumors, showing responses in patients, including those with squamous non-small cell lung cancer (NSCLC) who had previously failed PD-1 inhibitors.
IMM27M, a next-generation anti-CTLA-4 antibody, is designed to enhance ADCC activity, promoting intratumoral regulatory T cell depletion to increase efficacy and reduce toxicity associated with first-generation anti-CTLA-4 antibodies. It has completed a dose-escalation clinical trial, demonstrating anti-tumor activity in patients with advanced solid tumors and has moved into combination studies with IMM2510 in China as of July 2024.- Flcube.com
